BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 33271924)

  • 21. Lnc-TALC promotes O
    Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
    Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions.
    Belter A; Barciszewski J; Barciszewska AM
    PLoS One; 2020; 15(2):e0229534. PubMed ID: 32101575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
    Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S
    Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
    Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
    Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genome-Wide CRISPR-Cas9 Screening Identifies NF-κB/E2F6 Responsible for EGFRvIII-Associated Temozolomide Resistance in Glioblastoma.
    Huang K; Liu X; Li Y; Wang Q; Zhou J; Wang Y; Dong F; Yang C; Sun Z; Fang C; Liu C; Tan Y; Wu X; Jiang T; Kang C
    Adv Sci (Weinh); 2019 Sep; 6(17):1900782. PubMed ID: 31508283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells.
    MacLeod G; Bozek DA; Rajakulendran N; Monteiro V; Ahmadi M; Steinhart Z; Kushida MM; Yu H; Coutinho FJ; Cavalli FMG; Restall I; Hao X; Hart T; Luchman HA; Weiss S; Dirks PB; Angers S
    Cell Rep; 2019 Apr; 27(3):971-986.e9. PubMed ID: 30995489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma.
    Liu B; Zhou J; Wang C; Chi Y; Wei Q; Fu Z; Lian C; Huang Q; Liao C; Yang Z; Zeng H; Xu N; Guo H
    Cell Death Dis; 2020 May; 11(5):384. PubMed ID: 32439916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
    Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X
    Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
    Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
    Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair.
    Kim GW; Lee DH; Yeon SK; Jeon YH; Yoo J; Lee SW; Kwon SH
    Anticancer Res; 2019 Dec; 39(12):6731-6741. PubMed ID: 31810938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
    Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
    Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide.
    Johannessen TC; Hasan-Olive MM; Zhu H; Denisova O; Grudic A; Latif MA; Saed H; Varughese JK; Røsland GV; Yang N; Sundstrøm T; Nordal A; Tronstad KJ; Wang J; Lund-Johansen M; Simonsen A; Janji B; Westermarck J; Bjerkvig R; Prestegarden L
    Int J Cancer; 2019 Apr; 144(7):1735-1745. PubMed ID: 30289977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM.
    Stojcheva N; Schechtmann G; Sass S; Roth P; Florea AM; Stefanski A; Stühler K; Wolter M; Müller NS; Theis FJ; Weller M; Reifenberger G; Happold C
    Oncotarget; 2016 Mar; 7(11):12937-50. PubMed ID: 26887050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The CXCL12/CXCR4 axis confers temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1.
    Wang S; Chen C; Li J; Xu X; Chen W; Li F
    J Neurol Sci; 2020 Jul; 414():116837. PubMed ID: 32334273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells.
    Banelli B; Daga A; Forlani A; Allemanni G; Marubbi D; Pistillo MP; Profumo A; Romani M
    Oncotarget; 2017 May; 8(21):34896-34910. PubMed ID: 28432280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma.
    Chai Y; Wang C; Liu W; Fan Y; Zhang Y
    J Neurooncol; 2019 Sep; 144(2):293-301. PubMed ID: 31236818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long intergenic noncoding RNA 00021 promotes glioblastoma temozolomide resistance by epigenetically silencing p21 through Notch pathway.
    Zhang S; Guo S; Liang C; Lian M
    IUBMB Life; 2020 Aug; 72(8):1747-1756. PubMed ID: 32449315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism.
    Lee CAA; Banerjee P; Wilson BJ; Wu S; Guo Q; Berg G; Karpova S; Mishra A; Lian JW; Tran J; Emmerich M; Murphy GF; Frank MH; Frank NY
    J Biol Chem; 2020 May; 295(22):7774-7788. PubMed ID: 32317280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
    Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M
    J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
    Forte IM; Indovina P; Iannuzzi CA; Cirillo D; Di Marzo D; Barone D; Capone F; Pentimalli F; Giordano A
    Int J Oncol; 2019 Jun; 54(6):2189-2199. PubMed ID: 31081046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.